There has been an exploration of new targets in the management of hepatoblastoma including signal transducer and activator of transcription signaling 3 (STAT3) [71,72]; NOTCH receptors and their ligands [73]; PI3K/Akt, ERK and p38 signaling pathways [74]; GPC3 [75]; PIM Kinases [76]; ROCK1 [77]; mTOR and YAP [38]. Here, GPC3 is linked to hepatoblastoma.